Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SCI Interim / Quarterly Report 2012

Jan 23, 2013

52383_rns_2013-01-23_46bbe4f0-c28c-4812-a493-f8c076d78269.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

SCIPHARMTECH, ING.

簡報

ISO 14001 ISO 9001 BUREAU VERITAS BUREAU VERITAS Certification Certification

procedure ThainForm ForwardScon

If HescoryList.Count > 0 them Foregricket inn, Inchind to Michael

An Indian Medicine Enabled is False.

CODE BOUL CORE THE ATTENDANCE WILL FOR coast plasp: Dispatch; var ULL Reading at Gleversence-war

GestoryTodes ++ U) JALES HIFTOIVILLE COUNTY BAY ListoryList Delwie (History) Riccompladas in Riccorplice.Add

n, Micheylodes is Besinder.
Af Giovernale Com

UpilateCusto Im Zaluki Mei-Tudek in 1102. KE TILLISTER R. P.L. ED UE j. items, framers (0, US)

olas:

beals

$endf$

CANDIDATE ITODOLIWAY

員工數Employee:180 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣493佰萬元(NTD 493mn) 營業項目Business: 原料藥API(40.22%) 中間體Intermediate(48.64%) 特用化學品 Custom-made chemicals(11.14%)

公司概況 Outline

Y2012 Y2011
歐洲Europe 41.74% 31.17%
美洲America 22.11% 23.97%
亞洲Asia 18.15% 22.32%
國內Taiwan 18.00% 22.54%

計Total
100.00% 100.00%

Unit: K NTD

第一季 Q1 第二季Q
2
第三季Q
3
第四季Q
4
營收Sales 358,346 281,663 313,216 309,347
營業成本COGS 244,460 204,843 215,912 199,469
毛利Gross Profit 113,886 76,820 97,304 109,878
毛利率 GP Ratio 31.8% 27.3% 31.1% 35.5%
營業費用Operating Expenses (39,049) (34,291) (32,914) (35,926)
營業利益Operating Income 74,837 42,529 64,390 73,952
營業外損益Non-Operating In/Ex (7,124) 818 (3,891) (7,513)
稅前淨利 Net Profit before Tax 67,713 43,347 60,499 66,439
所得稅Income Tax (10,844) (8,299) (13,658)
稅後淨利Net Profit after Tax 56,869 35,048 46,841

產品組合-Products

Y2010 $\frac{0}{0}$
V.A. 20.63%
PGA 18.78%
Di-VaNa 15.96%
PPON $12.42\%$
M85 4.92%
Pent-2 $3.77\%$
M74 2.42%
DEK 2.12%
M 115 $2.04\%$
Biso-FA 2.03%
Total 85.09%
Y2010 % Y2011 % Y2012 %
V.A. 20.63% Di-VaNa 24.51% V.A. 18.66%
PGA 18.78% PGA 17.65% PGA 16.61%
Di-VaNa 15.96% V.A. 13.76% Di-VaNa 15.97%
PPON 12.42% PPON 10.70% PPON 7.88%
M85 4.92% M85 5.25% Pent-2 4.78%
Pent-2 3.77% Pent-2 3.73% 5-HMT 4.33%
M74 2.42% DBS 3.08% M85 3.89%
DEK 2.12% M115 2.55% DBS 2.73%
M115 2.04% M74 2.31% M115 2.59%
Biso-FA 2.03% NBE 1.87% M74 2.18%
Total 85.09% Total 85.40% Total 79.62%
Y2012 $\frac{0}{0}$
VA. 18.66%
PGA 16.61%
Di-VaNa 15.97%
PPON 7.88%
Pent-2 4.78%
5-HMT 4.33%
M85 3.89%
DBS 2.73%
M115 2.59%
M74 2.18%
Total 79.62%

V DEDPM.

SCI PHARMTECH, INC.

$\rightarrow VA$

NaVa

Valproic Acid (VA)

Pyrogallolaldehyde ( PGA) - Benserazide

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease

2個客戶 2 customers

Propiophenone (PPON)

Sales

第一項產品 First product

15個客戶 15 customers

52,253 47,758 37,509 38,665 60,410 - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2006 2007 2008 2009 2010 2011 2012 Sales Sales

Pent-2

Pentobarbital Sodium

鎮定安眠用之原料藥 API used as calmative

  • 2011年開始銷售6佰萬 6mn, starting in 2011. 2012銷售額23佰萬 23mn sales in 2012

第二項產品 Second product 5個客戶 5 customers

4個客戶 4 customers

Hydroxychloroquine

  • 2011年開始銷售10.8佰萬 10.8 mn, starting in 2011
  • 2012年銷售額33.6佰萬 33.6mn sales in 2012
  • 治療風濕性關節炎原料藥(Hydroxychloroquine sulfate) API : Hydroxychloroquine sulfate for rheumarthritis
  • 原料藥市場約20噸100 佰萬 API market: 20 MT, 100mn

Anti-inflammatory (Loxoprofen sodium) 2012年銷售5個客戶5佰萬 5 customers, 5 mn sales in 2012. 日本市場200-300公噸,200美金/公斤 Japan market:200-300MT at USD 200/kg

5-HMT – Ritonavir,Lopinavir

5-Wing– Ritonavir,Lopinavir 2012年開始銷售5.7佰萬 5.7mn, starting in 2012 愛滋病藥物之中間體 For AIDS treatment

產品介紹Product

Antidepressant ( Duloxetine ) 2013年底專利到期 Patent will expire in the end of 2013 2011銷售9.5佰萬予10個客戶 9.5 mn sales consisting of 10 customers in 2011 2012年銷售額8佰萬 8 mn sales in 2012 2011及2012年中間體S-MMAA分別銷售2佰萬及1佰萬 S-MMAA(Intermediate) : 2 mn in 2011, 1mn in 2012. 2010年美國市場製劑銷售值美金31億 USD 3.1 billion in formulation in America in 2010

4-CPE Cyclophosphamide:高效能原料藥 Cyclophosphamide: high-potent API

SCÏ

SCI PHARMTECH, INC.

Raw materials 歐、日、中國 大陸進口 From abroad

(原料、溶劑、觸媒)

化工分離(蒸餾、萃取、結晶等) Chemical segregations

GMP Status(GMP現況)

API CGMP
certified
(TFDA)
CEP
(EDQM)
DMF
(USA)
MF
(Japan)
DMF
(Canada)
Valproic
Acid
2003 2004 2003 2008 2008
Allopurinol 2004 2003 2011
Probucol 2004 2004
Sodium Valproate 2004 2006
Divalproex
Sodium
2005 2005 2010
Bisoprolol Fumarate 2006
Pentobarbital Sodium 2009 2011
Propafenone
Hydrochloride
2010 2012 2010 2012 2012
Methylphenidate HCl 2011
Duloxetine Hydrochloride 2012 2010/2011
Thiopental acid 2012
Loxoprofen Sodium Hydrate 2012 2011
Clindamycin Palmitate HCl 2011

敬 請 指 教